NCT06547229View on ClinicalTrials.gov

Clinicopathological Features and Genetic Susceptibility Screening of Recurrent Drug-induced Liver Injury

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

June 30, 2028

Conditions

Recurrent Drug-induced Liver Injury

Trial Locations (1)

100050

Liver Research Center, Beijing Friendship Hospital, Key Laboratory on Translational Medicine on Cirrhosis, National Clinical Research Center for Digestive Disease, Capital Medical University, Beijing, China, Beijing

All Listed Sponsors

lead

Beijing Friendship Hospital

OTHER

NCT06547229 - Clinicopathological Features and Genetic Susceptibility Screening of Recurrent Drug-induced Liver Injury | Biotech Hunter | Biotech Hunter